Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 10/20 | 0.52 |
| ▸ | CMA1 | P23946 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 7/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765599 | 0.86 | CTRC (0.54) | CTRCCMA1KDM4EALDH1A1ELANE | |
| SCHEMBL30765666 | 0.86 | KDM4E (0.51) | CTRCCMA1KDM4EALDH1A1ELANE | |
| SCHEMBL30765660 | 0.86 | KDM4E (0.51) | CTRCCMA1KDM4EALDH1A1ELANE | |
| SCHEMBL30765953 | 0.83 | ALDH1A1 (0.42) | CTRCCMA1KDM4EALDH1A1ELANE | |
| SCHEMBL7336849 | 0.82 | KDM4E (0.48) | CTRCCMA1KDM4EALDH1A1ELANE | |
| SCHEMBL6239360 | 0.82 | CMA1 (0.53) | CTRCCMA1KDM4EELANE | |
| SCHEMBL31558583 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7476393 | 0.82 | ALDH1A1 (0.47) | CTRCCMA1KDM4EALDH1A1ELANE | |
| Hydrochloric Acid SCHEMBL6805327 | 0.81 | CMA1 (0.53) | CTRCCMA1KDM4EELANE | |
| SCHEMBL6804111 | 0.81 | CMA1 (0.53) | CTRCCMA1KDM4EELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015223-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-03-21 | — | — | US | disclosed |
| US-6906068-B1 | Substituted polycyclic aryl and heteroaryl 1,2,4 - triazinones useful as anticoagulants | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| CN-1157380-C | Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents | �ź㴫 | 2004-07-14 | — | — | CN | disclosed |
| US-20040116430-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-6750342-B1 | INHIBITORS OF SERINE PROTEASES; ANTICOAGULANT | PHARMACIA CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-6653316-B1 | Coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2003-11-25 | — | — | US | disclosed |
| CN-1351593-A | Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents | PHARMACIA CO (US) | 2002-05-29 | — | — | CN | disclosed |
| EP-1178970-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087851-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069832-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054643-A1 | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade | TFPI, PLAT, SERPINC1 | CTRC 35/4885CMA1 138/4885KDM4E 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.